Orion Group Interim report January–September 2026: Strong financial performance and positive developments in the R&D pipeline

This is a paid press release. Contact the press release distributor directly with any inquiries.

ORION CORPORATION
INTERIM REPORT 1–9/2026
28 OCTOBER 2026 at 12:00 EET

July–September 2026 Highlights

Net sales totalled EUR 542.2 (July–September 2025: 423.2) million
Operating profit was EUR 209.9 (121.0) million
Basic earnings per share were EUR 1.19 (0.68)
Cash flow from operating activities per share was EUR 0.68 (0.55)
Phase 1 initiated with ODM-216, Orion’s first biologic clinical development asset
Interim results from the DASL-HiCaP Phase 3 trial were announced at the ESMO 2026 congress
Changes in the Orion Executive Team as of 1 January 2027

January–September 2026 Highlights

Net sales totalled EUR 1,481.5 (January–September 2025: 1,194.2) million
Operating profit was EUR 501.2 (303.5) million
Basic earnings per share were EUR 2.83 (1.71)
Cash flow from operating activities per share was EUR 2.89 (1.67)
The outlook for 2026 was upgraded after the review period in October: Net sales are estimated to be EUR 2,070 million to EUR 2,140 million. Operating profit is estimated to be EUR 730 million to EUR 790 million.







Profit before taxes, EUR million

Profit for the period, EUR million

Research and development expenses, EUR million

Capital expenditure excluding acquired in business combination, EUR million

Acquired in business combination, net of cash, EUR million
Interest-bearing net liabilities, EUR million

Cash flow from operating activities per share, EUR


Return on capital employed (before taxes), %
Return on equity (after taxes), %
Average number of personnel during the period

President and CEO Liisa Hurme:
Strong financial performance and positive developments in the R&D pipeline